Skip to content
DataLookout
Start free
Menu

MOANANCT07771400

Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtients

StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 2 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 5 more changesShow less
    • Eligibility criteria expanded, about 12 words
    • Start date changed from estimate of Sep 2026 to Sep 8, 2026
    • Secondary endpoints: details revised at 3 of 4 entries
    • Site details revised at 17 of 17 sites
    • Study description expanded, about 4 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Percentage of high-grade serous advanced ovarian cancer (AOC) cases overlapping FRα, HER2, PD-L1 positive expression and aberration positives for HRD and BRCA.
Timeframe: Data is extracted from retrospective medical records covering cases diagnosed from 2018 to 2024, with no prospective clinical follow-up or therapeutic interventions proposed.

Secondary (4)

Socio-demographic and clinicopathologic characteristics of Latin American advanced ovarian cancer (AOC) patients.
Treatment patterns of high-grade serous advanced ovarian cancer (AOC).
Folate receptor alpha (FRα), HER2, and PD-L1 expression by histologic advanced ovarian cancer (AOC) subtype.
Mutational status of HRD and BRCA in high-grade serous advanced ovarian cancer (AOC).

Arms and interventions

Retrospective Cohort

Patients diagnosed with ovarian, fallopian tube or peritoneal cancer with a) advanced stages stage III or IV by FIGO disease stage b) new diagnosis and persistent or recurrent disease.

Sites

17 sites in 4 countries

Brazil 9, Argentina 3, Mexico 3, Colombia 2